Guenter Niegisch (Günter Niegisch)

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 41

Top Topics

Combination Therapy

Histone Deacetylase

Top Venues

International journal of molecular sciences

Future oncology (London, England)

Journal of cellular and molecular medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Ioana Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Guenter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack, Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Theresa Mokry, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Dimo Dietrich, Jonas Saal, Joerg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua J Meeks, Francisco Emilio Vera-Badillo, José Alberto Nakauma-González, Joost Boormans, Kerstin Junker, Arndt Hartmann, Viktor Gruenwald, Michael Hudecek, Markus Eckstein
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Guenter Niegisch, Marc-Oliver Grimm, Fraence Hardtstock, Julia Krieger, Alexandra Starry, Ulrike Osowski, Silke Guenther, Barthold Deiters, Ulf Maywald, Thomas Wilke, Mairead Kearney
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis. Future oncology (London, England) 20 (19) (2024)
Sarah Meneceur, Caroline E De Vos, Patrick Petzsch, Karl Köhrer, Guenter Niegisch, Michèle Janine Hoffmann
New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma. Journal of cellular and molecular medicine 28 (9) (2024)
Guenter Niegisch, Marc-Oliver Grimm, Fraence Hardtstock, Julia Krieger, Alexandra Starry, Ulrike Osowski, Silke Guenther, Barthold Deiters, Ulf Maywald, Thomas Wilke, Mairead Kearney
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis. Future oncology (London, England) (2024)
Guenter Niegisch
Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer. The New England journal of medicine 390 (10) (2024)
Sarah Meneceur, Caroline E De Vos, Patrick Petzsch, Karl Köhrer, Guenter Niegisch, Michèle Janine Hoffmann
New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma. Journal of cellular and molecular medicine 28 (9) (2024)
Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Ioana Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Guenter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack, Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Theresa Mokry, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Dimo Dietrich, Jonas Saal, Joerg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua J Meeks, Francisco Emilio Vera-Badillo, José Alberto Nakauma-González, Joost Boormans, Kerstin Junker, Arndt Hartmann, Viktor Gruenwald, Michael Hudecek, Markus Eckstein
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (20) (2024)
Guenter Niegisch, Marc-Oliver Grimm, Fraence Hardtstock, Julia Krieger, Alexandra Starry, Ulrike Osowski, Barthold Deiters, Ulf Maywald, Thomas Wilke, Mairead Kearney
Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data. Journal of medical economics 27 (1) (2024)
Guenter Niegisch, Marc-Oliver Grimm, Fraence Hardtstock, Julia Krieger, Alexandra Starry, Ulrike Osowski, Barthold Deiters, Ulf Maywald, Thomas Wilke, Mairead Kearney
Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data. Journal of medical economics 27 (1) (2024)
Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Ioana Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Guenter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack, Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Theresa Mokry, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Dimo Dietrich, Jonas Saal, Joerg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua J Meeks, Francisco Emilio Vera-Badillo, José Alberto Nakauma-González, Joost Boormans, Kerstin Junker, Arndt Hartmann, Viktor Gruenwald, Michael Hudecek, Markus Eckstein
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (20) (2024)
Sofia Sturm, Guenter Niegisch, Joachim Windolf, Christoph V Suschek
Exposure of Bladder Cancer Cells to Blue Light (λ = 453 nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine. International journal of molecular sciences 25 (9) (2024)
Sarah Meneceur, Caroline E De Vos, Patrick Petzsch, Karl Köhrer, Guenter Niegisch, Michèle Janine Hoffmann
New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma. Journal of cellular and molecular medicine 28 (9) (2024)
Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Ioana Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Guenter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack, Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Theresa Mokry, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Dimo Dietrich, Jonas Saal, Joerg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua J Meeks, Francisco Emilio Vera-Badillo, José Alberto Nakauma-González, Joost Boormans, Kerstin Junker, Arndt Hartmann, Viktor Gruenwald, Michael Hudecek, Markus Eckstein
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (20) (2024)
Guenter Niegisch, Marc-Oliver Grimm, Fraence Hardtstock, Julia Krieger, Alexandra Starry, Ulrike Osowski, Silke Guenther, Barthold Deiters, Ulf Maywald, Thomas Wilke, Mairead Kearney
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis. Future oncology (London, England) (2024)
Guenter Niegisch, Marc-Oliver Grimm, Fraence Hardtstock, Julia Krieger, Alexandra Starry, Ulrike Osowski, Silke Guenther, Barthold Deiters, Ulf Maywald, Thomas Wilke, Mairead Kearney
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis. Future oncology (London, England) 20 (19) (2024)
Sarah Meneceur, Caroline E De Vos, Patrick Petzsch, Karl Köhrer, Guenter Niegisch, Michèle Janine Hoffmann
New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma. Journal of cellular and molecular medicine 28 (9) (2024)
Guenter Niegisch, Marc-Oliver Grimm, Fraence Hardtstock, Julia Krieger, Alexandra Starry, Ulrike Osowski, Silke Guenther, Barthold Deiters, Ulf Maywald, Thomas Wilke, Mairead Kearney
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis. Future oncology (London, England) 20 (19) (2024)
Guenter Niegisch
Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer. The New England journal of medicine 390 (10) (2024)
Thomas Hilser, Christopher Darr, Guenter Niegisch, Marco Julius Schnabel, Susan Foller, Lorine Häuser, Stefanie Zschäbitz, Jonas Lewerich, Philipp Ivanyi, Katrin Schlack, Pia Paffenholz, Eveline Daetwyler, Dora Niedersüß-Beke, Viktor Gruenwald
Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project. Cancers 16 (17) (2024)
Sofia Sturm, Guenter Niegisch, Joachim Windolf, Christoph V Suschek
Exposure of Bladder Cancer Cells to Blue Light (λ = 453 nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine. International journal of molecular sciences 25 (9) (2024)
Sofia Sturm, Guenter Niegisch, Joachim Windolf, Christoph V Suschek
Exposure of Bladder Cancer Cells to Blue Light (λ = 453 nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine. International journal of molecular sciences 25 (9) (2024)
Emil Novruzov, Dominik Schmitt, Katalin Mattes-György, Markus Beu, Yuriko Mori, Mardjan Dabir, Jan Philipp Radtke, Guenter Niegisch, Peter Albers, Lars Schimmöller, Gerald Antoch, Christina Antke, Frederik L Giesel, Eduards Mamlins
Intra-Individual Comparison of Physiologic [ 68 Ga]Ga-PSMA-11 and [ 18 F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: A Retrospective, Monocentric Analysis. Cancers 15 (10) (2023)
Marc Rehlinghaus, Philipp Rehker, Yue Che, Camilla Marisa Grunewald, Guenter Niegisch
[Neutropenia - when is GCSF support indicated?] Aktuelle Urologie (2023)
Camilla Marisa Grunewald, Vera Feldmeier, Tillmann Supprian, Peter Albers, Markus Giessing, Guenter Niegisch
Cognitive function in patients undergoing cystectomy for bladder cancer - results from a prospective observational study. Therapeutic advances in urology 14 (2022)
Aaron Burmeister, Alexa Stephan, Leandro A Alves Avelar, Melanie R Müller, Andrea Seiwert, Stefan Höfmann, Fabian Fischer, Hector Torres-Gomez, Michèle Janine Hoffmann, Guenter Niegisch, Felix Bremmer, Patrick Petzsch, Karl Köhrer, Peter Albers, Thomas Kurz, Margaretha A Skowron, Daniel Nettersheim
Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies. Molecular cancer therapeutics 21 (11) (2022)
Ananda Ayyappan Jaguva Vasudevan, Michèle Janine Hoffmann, Gereon Poschmann, Patrick Petzsch, Constanze Wiek, Kai Stühler, Karl Köhrer, Wolfgang A Schulz, Guenter Niegisch
Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression. Scientific data 9 (1) (2022)
Guenter Niegisch
Aktuelle Urologie 53 (2) (2022)
David Mally, David Pfister, Axel Heidenreich, Peter Albers, Guenter Niegisch
[Does robotic radical cystectomy affect oncological outcomes in bladder cancer patients?] Aktuelle Urologie 53 (2) (2022)
Jacqueline Schwartz, Manuela Schallenburger, Theresa Tenge, Yann-Nicolas Batzler, Daniel Schlieper, Detlef Kindgen-Milles, Stefan Meier, Guenter Niegisch, André Karger, Christoph Roderburg, Martin Neukirchen
Palliative Care e-Learning for Physicians Caring for Critically Ill and Dying Patients during the COVID-19 Pandemic: An Outcome Evaluation with Self-Assessed Knowledge and Attitude. International journal of environmental research and public health 19 (19) (2022)
Andrea Steuwe, Birte Valentin, Oliver T Bethge, Alexandra Ljimani, Guenter Niegisch, Gerald Antoch, Joel Aissa
Influence of a Deep Learning Noise Reduction on the CT Values, Image Noise and Characterization of Kidney and Ureter Stones. Diagnostics (Basel, Switzerland) 12 (7) (2022)
Michèle Janine Hoffmann, Sarah Meneceur, Katrin Hommel, Wolfgang A Schulz, Guenter Niegisch
Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells. Genes 12 (2) (2021)
Sophia Thy, Alexandra Hommel, Sarah Meneceur, Anna L Bartkowiak, Wolfgang A Schulz, Guenter Niegisch, Michèle Janine Hoffmann
Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment. Cancers 13 (6) (2021)
Lena Berning, David Schlütermann, Annabelle Friedrich, Niklas Berleth, Yadong Sun, Wenxian Wu, María José Mendiburo, Jana Deitersen, Hannah U C Brass, Margaretha A Skowron, Michèle Janine Hoffmann, Guenter Niegisch, Jörg Pietruszka, Björn Stork
Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment. Molecules (Basel, Switzerland) 26 (5) (2021)
Patcharawalai Whongsiri, Wolfgang Goering, Tobias Lautwein, Christiane Hader, Guenter Niegisch, Karl Köhrer, Michèle Janine Hoffmann, Wolfgang A Schulz
Many Different LINE-1 Retroelements Are Activated in Bladder Cancer. International journal of molecular sciences 21 (24) (2020)
Chenyin Wang, Alexandra Hamacher, Patrick Petzsch, Karl Köhrer, Guenter Niegisch, Michèle Janine Hoffmann, Wolfgang A Schulz, Matthias Ulrich Kassack
Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1. Cancers 12 (2) (2020)
Alexander Lang, Patcharawalai Whongsiri, Merve Yilmaz, Tobias Lautwein, Patrick Petzsch, Annemarie Greife, Cagatay Gunes, Karl Köhrer, Guenter Niegisch, Michèle Janine Hoffmann, Wolfgang A Schulz
Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines. Cancers 12 (4) (2020)
Alessandro Nini, Michèle Janine Hoffmann, Rita Lampignano, Robert Große Siemer, Guus van Dalum, Tibor Szarvas, Cristina Lopez Cotarelo, Wolfgang Arthur Schulz, Dieter Niederacher, Hans Neubauer, Nikolas Hendrik Stoecklein, Guenter Niegisch
Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells. Cytometry. Part B, Clinical cytometry 98 (4) (2020)
Ananda Ayyappan Jaguva Vasudevan, Michèle Janine Hoffmann, Michael L C Beck, Gereon Poschmann, Patrick Petzsch, Constanze Wiek, Kai Stühler, Karl Köhrer, Wolfgang A Schulz, Guenter Niegisch
HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition. International journal of molecular sciences 20 (9) (2019)
Margaretha A Skowron, Patrick Petzsch, Karin Hardt, Nicholas Wagner, Manfred Beier, Stefanie Thom, Matthias Drechsler, Harald Rieder, Karl Köhrer, Guenter Niegisch, Michèle Janine Hoffmann, Wolfgang A Schulz
Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines. Scientific reports 9 (1) (2019)
Aline Kaletsch, Maria Pinkerneil, Michèle Janine Hoffmann, Ananda Ayyappan Jaguva Vasudevan, Chenyin Wang, Finn K Hansen, Constanze Wiek, Helmut Hanenberg, Christoph G W Gertzen, Holger Gohlke, Matthias Ulrich Kassack, Thomas Kurz, Wolfgang A Schulz, Guenter Niegisch
Effects of novel HDAC inhibitors on urothelial carcinoma cells. Clinical epigenetics 10 (1) (2018)
Margaretha A Skowron, Margarita Melnikova, Joep G H van Roermund, Andrea Romano, Peter Albers, Juergen Thomale, Wolfgang A Schulz, Guenter Niegisch, Michèle J Hoffmann
Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines. International journal of molecular sciences 19 (2) (2018)